ECSP11011192A - Formulación de anticuerpo - Google Patents

Formulación de anticuerpo

Info

Publication number
ECSP11011192A
ECSP11011192A EC2011011192A ECSP11011192A ECSP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC 2011011192 A EC2011011192 A EC 2011011192A EC SP11011192 A ECSP11011192 A EC SP11011192A EC SP11011192 A ECSP11011192 A EC SP11011192A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
antibody
formulation
novel pharmaceutical
agglomerates
Prior art date
Application number
EC2011011192A
Other languages
English (en)
Spanish (es)
Inventor
Hans Joachim Wallny
Joachim Momm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011192A publication Critical patent/ECSP11011192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EC2011011192A 2008-12-10 2011-07-08 Formulación de anticuerpo ECSP11011192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
ECSP11011192A true ECSP11011192A (es) 2011-08-31

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011192A ECSP11011192A (es) 2008-12-10 2011-07-08 Formulación de anticuerpo

Country Status (31)

Country Link
US (3) US20110236398A1 (https=)
EP (4) EP2196476A1 (https=)
JP (6) JP6143416B2 (https=)
KR (2) KR101762966B1 (https=)
CN (3) CN104399076B (https=)
AU (1) AU2009324371B2 (https=)
BR (1) BRPI0922730A2 (https=)
CA (1) CA2745938C (https=)
CL (1) CL2011001406A1 (https=)
CO (1) CO6361952A2 (https=)
CY (2) CY1117735T1 (https=)
DK (2) DK2376533T3 (https=)
EC (1) ECSP11011192A (https=)
ES (2) ES2900624T3 (https=)
HR (2) HRP20211899T1 (https=)
HU (2) HUE028408T2 (https=)
IL (3) IL264316B2 (https=)
LT (1) LT3072906T (https=)
MA (1) MA33023B1 (https=)
MX (1) MX2011006242A (https=)
MY (2) MY166050A (https=)
NZ (1) NZ592918A (https=)
PE (1) PE20120342A1 (https=)
PL (2) PL3072906T3 (https=)
PT (2) PT2376533T (https=)
RU (2) RU2745601C2 (https=)
SI (2) SI2376533T1 (https=)
SM (1) SMT201600222B (https=)
TN (1) TN2011000229A1 (https=)
WO (1) WO2010066762A1 (https=)
ZA (1) ZA201103362B (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120076779A1 (en) 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
MA37946B1 (fr) * 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
JP2016502526A (ja) * 2012-11-16 2016-01-28 ノバルティス アーゲー 末梢動脈疾患を処置するためのＩＬ−１β結合抗体の使用
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
TW201513882A (zh) 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CA2959571A1 (en) * 2014-09-03 2016-03-10 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
LT3386541T (lt) 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
WO2018002031A1 (en) * 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
JP2019521161A (ja) * 2016-07-21 2019-07-25 ノバルティス アーゲー 肺サルコイドーシスの症状を治療するまたは軽減するためのＩＬ−１β結合抗体カナキヌマブの使用
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
CA3061874A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN111315412A (zh) * 2017-09-13 2020-06-19 诺华股份有限公司 Il-1b结合抗体用于治疗酒精性肝炎的用途
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
EP4268803A4 (en) * 2020-12-22 2025-04-16 Bio-Thera Solutions, Ltd. Stable antibody preparation, preparation method for same, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05010555A (es) * 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
CL2007003583A1 (es) * 2006-12-11 2008-07-18 Hoffmann La Roche Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
SI2376533T1 (sl) 2016-07-29
DK2376533T3 (en) 2016-06-27
LT3072906T (lt) 2021-12-27
IL276622A (en) 2020-09-30
MY166050A (en) 2018-05-22
RU2563179C2 (ru) 2015-09-20
BRPI0922730A2 (en) 2018-11-06
RU2015132431A3 (https=) 2018-12-24
JP2023109938A (ja) 2023-08-08
EP2376533A1 (en) 2011-10-19
IL212922B (en) 2019-02-28
MX2011006242A (es) 2011-06-24
HRP20160754T1 (hr) 2016-08-12
CN104399076A (zh) 2015-03-11
US8623367B2 (en) 2014-01-07
PL3072906T3 (pl) 2022-01-24
DK3072906T3 (da) 2021-12-13
IL264316A (en) 2019-02-28
US20200384108A1 (en) 2020-12-10
HRP20211899T1 (hr) 2022-03-04
EP2196476A1 (en) 2010-06-16
IL264316B1 (en) 2023-09-01
ZA201103362B (en) 2012-01-25
EP2376533B1 (en) 2016-03-30
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
IL212922A0 (en) 2011-07-31
RU2015132431A (ru) 2018-12-24
RU2011127913A (ru) 2013-01-20
SMT201600222B (it) 2016-08-31
HUE028408T2 (en) 2016-12-28
RU2745601C2 (ru) 2021-03-29
JP2012511540A (ja) 2012-05-24
PT3072906T (pt) 2021-12-14
CY1117735T1 (el) 2017-05-17
JP7286595B2 (ja) 2023-06-05
SI3072906T1 (sl) 2022-01-31
JP2020203889A (ja) 2020-12-24
CO6361952A2 (es) 2012-01-20
CN114225022A (zh) 2022-03-25
JP2018168158A (ja) 2018-11-01
HK1159130A1 (zh) 2012-07-27
WO2010066762A1 (en) 2010-06-17
CN102245639A (zh) 2011-11-16
IL264316B2 (en) 2024-01-01
KR101762966B1 (ko) 2017-07-31
PT2376533T (pt) 2016-07-13
HUE056626T2 (hu) 2022-02-28
AU2009324371B2 (en) 2013-10-10
JP6143416B2 (ja) 2017-06-07
CL2011001406A1 (es) 2012-03-30
TN2011000229A1 (en) 2012-12-17
CN102245639B (zh) 2014-12-24
CN104399076B (zh) 2021-09-14
PE20120342A1 (es) 2012-04-24
JP2015231997A (ja) 2015-12-24
ES2900624T3 (es) 2022-03-17
JP2026021446A (ja) 2026-02-10
PL2376533T3 (pl) 2016-09-30
EP3072906A1 (en) 2016-09-28
US20120315285A1 (en) 2012-12-13
CA2745938A1 (en) 2010-06-17
EP3792282A1 (en) 2021-03-17
EP3072906B1 (en) 2021-09-08
KR20120009421A (ko) 2012-01-31
US20110236398A1 (en) 2011-09-29
MA33023B1 (fr) 2012-02-01
AU2009324371A1 (en) 2011-06-23
CA2745938C (en) 2018-04-24
KR20170044211A (ko) 2017-04-24
ES2579835T3 (es) 2016-08-17
CY1124844T1 (el) 2022-11-25

Similar Documents

Publication Publication Date Title
ECSP11011192A (es) Formulación de anticuerpo
CY1125697T1 (el) Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων
AR111455A1 (es) Formulación estable de anticuerpo
PH12014502778A1 (en) Antibody formulation
CL2015001959A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
AR079556A1 (es) Formacion de anticuerpos
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2013002597A (es) Arilpirrolidinas pesticidas.
EP2799543A4 (en) HUMANIZED ANTI-EPIREGULIN ANTIBODY AND CANCER THERAPY AGENTS WITH THESE ANTIBODY AS ACTIVE AGENT
CO7101240A2 (es) Compuestos ß-lactámicos sustituidos con amidina, su preparación y uso como agentes bacterianos
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
MX357936B (es) Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente.
MX385093B (es) Formulaciones de espuma y aparatos para su suministro.
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CO2017007316A2 (es) Formulación farmacéutica
BR112013009415A2 (pt) composto de éter arilóxidihalo-propenil e uso destes
CO6321223A2 (es) Formulacion farmaceutica solida que contiene ciclostazol
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
CL2015003191A1 (es) N-(2-fluoro-2-fenetil)carboxamidas como nematicidas y endoparasiticidas
ES2604837T3 (es) Formulación de liberación sostenida que contiene anticuerpos para administración ocular
CL2013000134S1 (es) Asiento reposera en forma de cuerpo de mujer estilizada semi recostada con sus piernas extendidas y unidas, el tronco inclinado respecto de las piernas que quedan horizontales, donde el tronco de la mujer esta truncado sin cabeza ni brazos.
IN2014DN10134A (https=)
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.